Promotion of skin tumours by TPA in the progeny of mice exposed pre-natally to DMBA

Authors:
  • NNN. Napalkov
    N. Napalkov
  • ALA. Likhachev
    A. Likhachev
  • VAV. Anisimov
    V. Anisimov
  • ALA. Lokitonov
    A. Lokitonov
  • MZM. Zabezhinski
    M. Zabezhinski
  • AOA. Ovsyannikov
    A. Ovsyannikov
  • JWJ. Wahrendorf
    J. Wahrendorf
  • HBH. Becher
    H. Becher
  • LTL. Tomatis
    L. Tomatis

Abstract
Pregnant SHR mice were treated once with 7,12-dimethylbenz[a]anthracene (DMBA) on day 17-19 of gestation, and F1 and F2 descendants received multiple skin applications of 12-O-tetradecanoylphorbol-13-acetate (TPA) twice a week for 24 weeks beginning at 12 weeks of age. Post-natal promoter treatment resulted in a high incidence of skin tumours in F1 and F2 mice (37.3 and 19.7%, respectively), whereas only 6.6% of control animals treated with TPA only developed skin tumours. DMBA was shown previously to be capable of initiating skin carcinogenesis transplacentally; however, our results on the second generation provide suggestive evidence of hereditary transmission of at least part of the initiating action of this carcinogen.

This publication has 13 references indexed in Scilit: